enGene Holdings Inc. (NASDAQ:ENGNW – Get Free Report) shot up 15.9% on Friday. The stock traded as high as $0.2399 and last traded at $0.22. 2,660 shares traded hands during trading, a decline of 83% from the average daily volume of 15,988 shares. The stock had previously closed at $0.1899.
enGene Price Performance
The business has a 50-day simple moving average of $0.21 and a 200 day simple moving average of $0.55.
enGene Company Profile
enGene Inc is a clinical-stage biotechnology company developing non-viral gene therapies for diseases affecting the gastrointestinal and genitourinary systems. The company’s technology is designed to deliver therapeutic DNA directly to targeted tissues, with the goal of producing localized treatment while limiting systemic exposure.
enGene’s lead investigational product is detalimogene voraplasmid, also known as EG-70, an intravesical gene therapy being developed for patients with high-risk non-muscle-invasive bladder cancer, including disease that has not responded adequately to Bacillus Calmette-Guérin therapy.
Featured Articles
- Five stocks we like better than enGene
- Bloom Energy Just Reported—Its Biggest Order Is Still Waiting on a Pipeline
- Why Western Digital’s AI Storage Boom Defies the Chip Sell-Off
- Grand Canyon Education Strengthens Its Outlook, But Wall Street Remains Divided
- Amex Stock Slides on Job Cuts, But the Real Story Is Macro
Receive News & Ratings for enGene Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for enGene and related companies with MarketBeat.com's FREE daily email newsletter.
